Bio-Rad Laboratories Inc. reported its earnings for the second quarter of 2025, revealing a modest increase in net sales and a stable financial performance. Despite a challenging market environment, ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), and Gencurix, Inc. (KOSDAQ: 229000), announced the signing of a strategic agreement establishing Bio-Rad as the exclusive distributor of Gencurix’ ...
NEW YORK – Bio-Rad Laboratories announced Wednesday that it has expanded a prior precision medicine partnership with South Korea-based diagnostics developer Gencurix. Financial terms of the deal were ...
Extended Partnership Agreement Will Expand Availability Across Europe of Gencurix’ In Vitro Diagnostic (IVD) Assays Using Droplet Digital™ PCR (ddPCR™) for Clinical Testing of Critical Oncology ...
In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Bio-Rad Laboratories, Inc. stands amongst them. Bio-Rad Laboratories, Inc. (NYSE:BIO), a global ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced today that the company’s ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced today that the company’s management will host an informational ...
We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Bio-Rad Laboratories, Inc. stands tenth on our list and is currently making waves for launching a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback